Abstract
Malignant hyperthermia during surgery represents a significant challenge for anesthesiologists due to its high mortality rate and the risk of long-term physiological damage. Despite preventive measures, malignant hyperthermia cases continue to be reported. The standard and effective response involves the prompt administration of dantrolene, a specific antidote. However, dantrolene availability can differ across countries and regions; not all healthcare facilities can guarantee its immediate availability for early intervention. This case report details the successful management of malignant hyperthermia in an adult during surgery without the use of dantrolene.